From the Data Center to the Doctor's Office: How are NVIDIA and AMD using accelerated computing to transform healthcare and drug discovery?

NVIDIA is transforming healthcare by creating specialized, end-to-end platforms as part of its strategy to "Drive Growth in Key Verticals." The company's goal is to "Transform Healthcare with AI" by providing researchers and clinicians with purpose-built tools. Key initiatives include expanding the "NVIDIA Clara™" suite of computing platforms and services for medical imaging and life sciences, and advancing the "NVIDIA BioNeMo™" platform, which offers generative AI models specifically for drug discovery. This platform-based approach provides a highly integrated and optimized environment, accelerating the path from research to clinical application.

AMD's approach to healthcare and drug discovery is centered on providing high-performance, versatile hardware and an open software ecosystem. Rather than building branded vertical platforms, AMD's strategy is to "Enable leadership AI capabilities across [its] entire product portfolio," making its powerful EPYC CPUs and Instinct GPUs ideal for the computationally intensive workloads common in scientific research. The company also develops "Application-Specific Embedded Solutions" leveraging its adaptive computing technology for use in medical devices. This positions AMD's hardware as a powerful and flexible engine for discovery, allowing research institutions the freedom to build their own solutions on top of AMD's open ROCm software stack.